Omalizumab group, N= 105 (A) Omalizumab group, N= 105 (A) Mepolizumab group, N= 62 (B) Mepolizumab group, N= 62 (B)
Severe asthma, non-biologic group, N=178 (C)
Severe asthma, non-biologic group, N=178 (C)
P-values
P-values
Mean (SD) / Median (IQR) Missing Mean (SD) / Median (IQR) Missing Mean (SD) / Median (IQR) Missing A vs C B vs C
Annualised rate of exacerbations, median (IQR) 5 (3) † 2 4 (5) † 1 5 (3) ‡ 32 0.391 0.744
Annualised rate of AHE, median (IQR) 1 (2) † 9 0 (1) † 3 0 (1) ‡ 1 0.238 0.184
Maximum Eos count in the past year, median (IQR) - cells/µL 250 (400) † 9 500(400) † 0 200 (300) ‡ 49 0.052 <0.001
ACQ6, median (IQR) 3 (1.79) § 25 2.67 (1.67) § 3 3 (1.8) ‡ 11 0.594 0.795
FENO, median (IQR) - ppb 30 (38) § 27 36 (52) § 3 16.85 (24.65) ‡ 50 0.007 <0.001
Clinic FEV1 %, mean (SD) 66.59 (20.77) § 6 67.1 (20.77) § 2 76.78 (23.37) ‡ 57 0.001 0.007
Maintenance OCS dose, median (IQR) - mg § 10 (10) 1 10 (10) 0 n/a n/a n/a n/a
BMI, median (IQR) – kgm-2 30.60 (9.75) 0 28.95 (28.95) 0 30.8 (10.8) 3 0.502 0.214
Age of asthma diagnosis, median (IQR) - y 10 (25) 4 28 (38.5) 1 20 (35) 9 0.007 0.039
Age, median (IQR) - y 52 (18.5) 0 61 (19) 0 54.5 (25) 0 0.643 0.015
Percentage (N) Missing Percentage (N) Missing Percentage (N) Missing P-value P-value
Multiple AHE (>1), Yes 31.3% (30) † 9 16.9% (10) † 3 24.3% (43) ‡ 5 0.215 0.242
On Maintenance OCS, Yes 47.6% (50) § 0 72.6% (45) § 0 30.6% (53) ‡ 1 0.004 <0.001
Adult-onset asthma, Yes 37.6% (38) 4 60.7% (37) 1 52.7% (89) 9 0.017 0.282
Sex, Male 33.3% (35) 0 53.2% (33) 0 29.8% (53) 0 0.532 0.001
Ethnicity, White 87.6% (92) 0 91.9% (57) 0 94.9% (169) 0 0.026 0.362
Rhinitis, Ever 73.6% (64) 18 72.9% (43) 3 60.1% (95) 10 0.035 0.082
GORD, Ever 64.4% (67) 1 67.2% (41) 1 65.3% (111) 8 0.883 0.875
Smoking, Ever 43.8% (46) 0 56.5% (35) 0 47.5% (84) 1 0.552 0.223
Atopy (SPT / sIgE positive) 100% (105) 0 50.0% (31) 0 52.8% (94) 0 <0.001 0.703
Obesity (BMI≥30kgm-2), Ever 52.4% (55) 0 41.9% (26) 0 52.6% (92) 3 0.975 0.097
Admitted to ICU for asthma, Ever 27.9% (29) 1 35.5% (22) 0 32.6% (58) 0 0.410 0.677
Intubated for Asthma, Ever 14.4% (15) 1 14.5% (9) 0 17.4% (31) 0 0.512 0.598
Dysfunctional breathing, Ever 51.5% (51) 6 40.0% (24) 2 55.1% (92) 11 0.572 0.045
ILO, Ever 19.4% (18) 12 13.8% (8) 4 13.2% 921) 19 0.193 0.911
Depression, Ever 31.9% (29) 14 28.3% (17) 2 42.8% (68) 19 0.089 0.051
Anxiety, Ever 30.8% (28) 14 27.1% (16) 3 38.0% (60) 19 0.252 0.136
Bronchiectasis, Ever 15.5% (16) 2 19.4% (12) 0 14.2% (25) 2 0.762 0.336
Salicylate sensitivity, Ever 33.0% (34) 2 19.4% (12) 0 27.8% (49) 2 0.416 0.188
ABPA, Ever 12.6% (13) 2 12.9% (8) 0 5.2% (9) 4 0.027 0.081
Sulphite sensitivity, Ever 8.7% (9) 2 9.7 % (6) 0 7.4% (13) 3 0.696 0.590
COPD, Ever 5.8% (6) 2 9.7 % (6) 0 10.8% (19) 2 0.161 0.805
Nasal polyps, Ever 21.4% (21) 7 34.5% (20) 4 19% (31) 15 0.635 0.019
Nasal (polyps / sinus) surgery, Ever 31.6% (30) 10 31.7% (19) 2 19.3% (31) 17 0.025 0.050
Urticaria or Angioedema, Ever 12.6% (13) 2 8.1% (5) 0 6.8% (12) 2 0.101 0.776
OSA, Ever 4.9% (5) 2 6.5% (4) 0 11.5% (20) 4 0.062 0.259
Eczema, Ever 31.7% (33) 1 27.4% (17) 0 21.6% (38) 2 0.060 0.349